Brief: Bellerophon Therapeutics Announces License Agreement For The Commercialization Of Inopulse® In Greater China With Baylor Biosciences
05/01/2023 15:12
Jan 5 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS ANNOUNCES LICENSE AGREEMENT FOR
THE
COMMERCIALIZATION OF INOPULSE® IN GREATER CHINA WITH BAYLOR
BIOSCIENCES
* BELLEROPHON THERAPEUTICS- TO RECEIVE A LICENSE PAYMENT OF
$6
MILLION, PAYABLE WITHIN 90 DAYS SUBJECT TO CERTAIN CLOSING
CONDITIONS SET FORTH IN AGREEMENT
* BELLEROPHON THERAPEUTICS INC - ENTITLED TO ROYALTIES OF 5%
ON
NET SALES RESULTING FROM ALL OF LICENSED INOPULSE INDICATIONS
WITHIN GREATER CHINA
* BELLEROPHON THERAPEUTICS INC - BAYLOR BIOSCIENCES WILL
RECEIVE
EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE INOPULSE WITHIN
GREATER CHINA
Source text for Eikon: ID:nGNX6pmYTQ
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen